Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03097068 · ClinicalTrials.gov registry record · Phase 4
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
A Phase 4 study of Diabetic Macular Edema, sponsored by Vitreo-Retinal Associates, Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03097068: Completed Phase 4 study of Diabetic Macular Edema, sponsored by Vitreo-Retinal Associates, Michigan.
NCT03097068 is a Phase 4 study of Diabetic Macular Edema that has completed, run by Vitreo-Retinal Associates, Michigan. The registered enrollment target is 10 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03097068, a Phase 4 study of Diabetic Macular Edema, has completed, sponsored by Vitreo-Retinal Associates, Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg Lucentis.
Primary Outcome
An aqueous humor specimen was obtained at baseline and at 12 weeks to determine if the levels of VEGF had decreased with treatment.
Conditions Studied
Interventions
- DRUG Lucentis
Study Locations (1)
Michigan
- Vitreo-Retinal Associates - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-04-19 |
| Est. Completion | 2018-02-02 |
| Phase | Phase 4 |
What the finished NCT03097068 record still lists
NCT03097068 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Lucentis is the first listed.
NCT03097068 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT03097068 about?
NCT03097068 is a clinical study titled "Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis". The protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg Lucentis.
What is the current status of trial NCT03097068?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2017-04-19. Estimated completion is 2018-02-02.
What conditions does trial NCT03097068 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT03097068?
The interventions under investigation include: Lucentis (DRUG).
Who is sponsoring clinical trial NCT03097068?
This trial is sponsored by Vitreo-Retinal Associates, Michigan, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03097068 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03097068's enrollment target sits among peer trials
10 61st of 63 higher than 2 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 4
-
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 4
-
Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
ACTIVE NOT RECRUITING · Phase 4
-
Ocular Safety and Usability Study for FYB203 PFS
COMPLETED · Phase 4
-
IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
COMPLETED · Phase 4
-
Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI